Apricus Biosciences Reports on Corporate Goals for 2013

Apricus Biosciences

(www.apricusbio.com) today announced its corporate goals for 2013, which includes focusing its corporate strategy on its high value assets such as Vitaros® for erectile dysfunction ("ED") and Femprox® for female sexual arousal disorder ("FSAD") and plans to seek a buyer for its oncology supportive care products, which consists of two approved products now sold in the United States. The planned divestiture will allow Apricus Bio to better align its resources with its main corporate objectives. Rusty Ray, Chairman of the Board of Apricus Bio, commented, "The Board of Directors believes that the greatest potential for shareholder value creation is in the further development and commercialization, through strategic partnerships, of the Company's primary commercial and pipeline assets, particularly Vitaros® (alprostadil 0.3% topical cream) and Femprox® (alprostadil 0.4% topical cream) for male and female sexual health. Both products utilize Apricus Bio's proprietary NexACT® transdermal delivery platform. The Company's resources therefore, will be directed toward these key assets, a decision that will concentrate the Company's strategic focus and better allow us to deliver value through 2013 and beyond." Apricus Bio's oncology supportive care business includes the rights to